Kahuna Workforce Solutions Secures $21 Million in Series B Funding from Resolve Growth Partners to Advance Skills Management Technology for Frontline Workers
29.11.2023 19:08:00 EET | Business Wire | Press release
Kahuna Workforce Solutions, the leading provider of operational skills and competency management software, today announced a $21 million Series B funding round led by Resolve Growth Partners. This investment marks a significant milestone in Kahuna’s growth journey and solidifies the criticality of skills management for industries with technical frontline workforces.
As organizations navigate an ever-evolving and complex landscape, understanding, validating, and aligning workforce skills to strategic business objectives is central to operating at the highest level. Kahuna is at the forefront of skills management technology, equipping organizations with actionable skill insights for effective assessment, training and development, and staffing and deployment initiatives, ultimately enabling resilient operations, improved productivity, and a more competitive workforce.
Kahuna’s customer base of leading Fortune 500 energy, manufacturing, and field service organizations, and world-renowned healthcare systems, is a testament to the platform’s scalability and robustness in meeting the rigorous demands of complex operational needs. The flagship skills management platform digitizes granular skills data, removing the burden that often comes with tracking skills manually in Excel spreadsheets or a traditional HRIS. Organizations can dynamically track skills, identify and analyze skills gaps, and provide targeted development opportunities whether at the bedside, in the field, or on the plant floor.
Kahuna plans to use the growth funding strategically to accelerate and enhance product development and innovation; expand its team by adding key roles across sales and marketing, product development, customer success, and engineering; and increase operational capabilities to continue supporting global customers as they adopt skills-based strategies to achieve operational excellence.
“We are thrilled to work with Resolve as Kahuna begins the next growth phase. Their expertise in enterprise software, and commitment to innovation and continuous improvement fully aligns with our mission, vision, and goals for Kahuna,” said Jai Shah, CEO of Kahuna Workforce Solutions. “This funding fuels our ability to provide mission-critical skills management solutions and support as we revolutionize how organizations manage and optimize workforce skills and capabilities.”
“Kahuna stands out as a category leader, as demonstrated by the quality of logos in their portfolio. They offer best-in-class skills management software and create true partnerships with customers to achieve transformative business value and operational outcomes,” said Jit Sinha, Co-Founder and Partner at Resolve Growth Partners. “Kahuna’s extensive understanding of market needs positions them uniquely in this space. Our investment is a testament to the confidence we have in Kahuna to continue leading and offering unparalleled solutions to meet the evolving needs of customers globally.”
With Resolve’s partnership, this round of funding positions Kahuna to expand its impact, empowering organizations to build resilient, future-ready workforces with operational skilling tools and initiatives for frontline workers.
About Resolve Growth Partners
Resolve Growth Partners is a growth equity firm focused on investing in B2B software companies and enabling passionate, committed entrepreneurs to accelerate growth. Resolve provides expertise and repeatable best practices across talent, go-to-market, and operations. For more information on Resolve, visit http://www.resolvegrowth.com.
About Kahuna Workforce Solutions
Kahuna Workforce Solutions is the only skills management software built for operations, learning, and human resources. Kahuna equips enterprise organizations with validated skills data to understand workforce capability, align talent supply and demand, and increase the return on training investment. Across a wide array of industries including healthcare, energy, manufacturing, and aerospace, Kahuna helps organizations build a more skilled, competitive workforce. For more information, visit https://kahunaworkforce.com/.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20231129383752/en/
Contact information
Torrye Metoyer
Director of Marketing
torrye.metoyer@kahunaworkforce.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Murata Launches Ultra-Low Power AMR Sensors to Boost Battery Life in Healthcare and Wearables Devices27.4.2026 05:00:00 EEST | Press release
Murata Manufacturing Co., Ltd. (TOKYO: 6981) (ISIN: JP3914400001) has commenced mass production of its MRMS166R and MRMS168R anisotropic magnetoresistance (AMR) sensors for healthcare, wearable, and IoT devices. The MRMS166R is the first AMR sensor to combine an average current consumption of 20 nA with operation from a 1.2 V supply, enabling extended battery life in coin cell-powered systems. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260413296947/en/ [Murata Manufacturing Co., Ltd.] AMR sensor The devices are solid-state magnetic sensors used for switching applications. They detect the presence or absence of a magnetic field and generate an output signal that system logic uses to control functions such as transitions between active and sleep modes. This enables contactless switching without mechanical components, improving reliability, and supporting sealed, miniaturized designs. Automatic switching between active and
Sun Pharma signs Definitive Agreement to Acquire Organon27.4.2026 02:51:00 EEST | Press release
Sun Pharmaceutical Industries Limited(Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715) (together with its subsidiaries and/or associated companies, “Sun Pharma”) and Organon & Co. (NYSE: OGN) (“Organon”) today announced that they have entered into a definitive agreement under which Sun Pharma will acquire all outstanding shares of Organon for US$ 14.00 per share in an all‑cash transaction with an enterprise valuation of US$ 11.75 billion. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260426881370/en/ Organon is a global healthcare company formed through a spinoff from Merck, known as MSD outside of the United States and Canada, in 2021. Organon has a legacy of deep trust and strong brand equity among HCPs, patients, regulators and other stakeholders. A global leader in women’s health, the company’s portfolio includes more than 70 products across Women’s Health and General Medicines, which includes biosimila
PMC Organometallix Announces Price Increase on All Products25.4.2026 00:02:00 EEST | Press release
Due to significant changes in market conditions, PMC Organometallix, Inc. announces that effective May 1, 2026, or as contracts permit, prices across all product lines globally will increase by 10-25%. This adjustment is driven by sustained cost pressures from key inputs including rising raw material costs and escalating freight and logistics expenses. While the company has been absorbing these increases, the current economic environment brought on by the geopolitical crisis of the Iran conflict requires this adjustment to continue providing the high-quality, consistent materials and supply reliability that customers expect. PMC Organometallix will implement these changes in a transparent, collaborative manner and values your partnership while navigating these economic challenges. Customers with questions or to discuss a specific situation should contact their account representative. About PMC Group PMC Group is a growth-oriented, diversified, global chemicals and plastics company deli
Frankfurt Higher Regional Court upholds BESREMi ® arbitral award in favor of AOP Health24.4.2026 19:52:00 EEST | Press release
Today, the Higher Regional Court of Frankfurt upheld the February 20251 partial final ICC arbitral award in favor of AOP Orphan Pharmaceuticals GmbH (“AOP Health”) in its dispute with PharmaEssentia Corp. (“PharmaEssentia”). The ruling confirms the award which found the Taiwanese company to be liable for certain damages. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260424005227/en/ Portrait Dr. Rudolf Widmann, Founder AOP Health Credit: AOP Health/Daniel Ospelt Dr. Rudolf Widmann, one of the two founders of AOP Health, explains: “We very much welcome the Frankfurt Higher Regional Court’s decision that confirms our position. In the interest of our patients, we are dedicated to maintaining stable and sustainable access to BESREMi® and to responsibly navigating future challenges.” The Product in Dispute The conflict centers around BESREMi® (ropeginterferon alfa-2b), a product launched in 2019 and developed by AOP Health into
Compass Pathways Announces FDA Granted NDA Rolling Review Request and Awarded Commissioner's National Priority Voucher24.4.2026 17:37:00 EEST | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, today announced the U.S. Food and Drug Administration (FDA) granted Compass NDA rolling review request and selected COMP360, Compass’ proprietary formulation of synthetic psilocybin, for the Commissioner's National Priority Voucher (CNPV) program for treatment-resistant depression (TRD). Companies selected for the voucher program will be entitled to benefits including enhanced communications and a shortened 1-2 month review time following filing of a New Drug Application (NDA), while maintaining FDA’s rigorous safety and efficacy standards. “We are honored and grateful to be selected for the CNPV which is a clear validation of both the urgent unmet need facing millions of people living with treatment resistant depression and the innovative science of COMP360,” said Kabir Nath, Chief Executive Officer of Compass Pathways. “As the most advan
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
